meplazumab

Research use only, not for human use.

meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.

meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients. The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5]; p=0.014, HR=0.37, 95%CI[0.155-0.833]). The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group. No adverse effect was found in meplazumab-treated patients. Interpretation:Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile.

——

——

——

Others

Other Targets

Others

——

——

——

——

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years